close
Enquiry IconContact Us
Logo
  • Choose License Type

The Global Acute Ischemic Stroke (AIS) Market, by Therapeutics (Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America)  was valued at US$ 8,517.0 Million in 2021 and is projected to exhibit a CAGR of 4.0% during the forecast period (2021-2028).

The key market players are focusing on the introduction and approval of novel therapies for the treatment of acute ischemic stroke (AIS), which is projected to provide a profitable opportunity for industry participants to introduce their novel therapies. For instance, in October 2020, Athersys (a clinical-stage biotechnology company) prepared MultiStem stroke therapy for Japan's RegenMed Law Approval. MultiStem cell therapy from Athersys is in Phase III clinical trials in the U.S. and in Japan with Japanese partner Healios K.K. to treat ischemic stroke and acute respiratory distress syndrome (ARDS). In Japan, the therapy has Fast Track designation given by the US Food and Drug Administration (FDA). It is believed to be the only cell therapy treatment for ARDS in the U.S. that has both FastTrack and RMAT designations.

Global Acute Ischemic Stroke (AIS) Market – Impact of Coronavirus (COVID-19) Pandemic

COVID-19 pandemic has affected various industries globally. The players operating in the global acute ischemic stroke (AIS) market are facing major challenges on various fronts due to the COVID-19 pandemic. According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, the number of COVID-19 cases reported globally, as of October 20, 2021, are approximately 241,411,380 confirmed cases with 4,912,112 deaths.

The coronavirus pandemic has negatively impacted the development, production, and supply of pharmaceutical products and affected growth of the medication used in treatment of acute ischemic stroke (AIS) manufactured by various companies across the regions such as North America, Europe, and Asia Pacific. Moreover, the supply and production of pharmaceutical products is also affected due to COVID-19 pandemic lockdown imposed globally. This lockdown has resulted in closure of industrial establishments, except manufacturing of essential commodities, and disruption in supply chain of the pharmaceutical products.

Browse 25 Market Data Tables and 26 Figures spread through 149 Pages and in-depth TOC on “Global Acute Ischemic Stroke (AIS) Market”- Forecast to 2028, Global Acute Ischemic Stroke (AIS) Market, by Therapeutics (Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) - Forecast to 2028

To know the latest trends and insights prevalent in the Global Acute Ischemic Stroke (AIS) Market, click the link below:

https://www.coherentmarketinsights.com/market-insight/acute-ischemic-stroke-therapeutics-market-4483

The increasing prevalence of chronic disease such as diabetes, obesity, and others is anticipated to drive the growth of global acute ischemic stroke (AIS) market over the forecast period. For instance, as per the 2021 Heart Disease & Stroke Statistical Update Fact Sheet provided by the American Heart Association, around 237.9 million males and 222.0 million females worldwide had diabetes in 2019. Moreover the economic burden of diabetes globally was approximately US$ 1.3 trillion in 2015. It is estimated to increase to US$ 2.1 to US$ 2.5 trillion by 2030.

Key Takeaways of the Global Acute Ischemic Stroke (AIS) Market:

  • The global acute ischemic stroke (AIS) market is expected to exhibit a CAGR of 4.0% during the forecast period, owing to increasing prevalence of overweight and obesity as obesity is associated with an increased risk of developing cardiovascular disease. For instance, according to the World Health Organization (WHO), in 2016, around two billion adults were overweight, of which 650 million were considered obese. This corresponds to 39% (39% of men and 40% of women) of overweight adults aged 18 and over and 13% of obesity. It is estimated that 2.7 billion adults will be overweight, more than one billion will be obese, and 177 million adults will be severely obese by 2025, worldwide.
  • Among therapeutics, tissue plasminogen activator segment is expected to lead the global acute ischemic stroke (AIS) market. The 2018 guidelines from the American Heart Association (AHA) and the American Stroke Association (ASA), stated that intravenous tissue plasminogen activator (tPA), is the most effective treatment for AIS when given within four and a half hours after the onset of a stroke.
  • Major players operating in the global acute ischemic stroke (AIS) market include F. Hoffmann-La Roche AG, Boehringer Ingelheim, Bayer AG, Pfizer Inc., Biogen, Daiichi Sankyo, Bristol-Myers Squibb, Johnson & Johnson, AstraZeneca, SanBio and Athersys Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly subscribe for our latest news & articles.